WhiteLab Genomics and the Accelerator for Technological Research in Genomic Therapies Collaborate on AI for Gene Therapy Bioproduction

As part of this collaboration, teams from the Accelerator for Technological Research in Genomic Therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors, which will be used to identify the parameters allowing for a significant increase in vector quality as well as their production yields, and to reduce the production costs.

Cell and gene therapy is a new biomedical approach that can treat a growing number of genetic and acquired diseases such as cancer. To keep up with their growth, the pharmaceutical manufacturing of these Advanced Medicinal Therapies needs to accelerate in terms of standardization and process control. Because purifying lentiviral vectors remains complex and at critical capacity, the partnership is focused on manufacturing lentiviral vectors, which are used in many gene therapies approaches, including the manufacture of CAR-T cells.

The teams will utilize AI to analyze information from multiple sources to optimize existing processes and develop new ones. The approach used with the lentiviral vectors will apply to various bioproducts.

This initiative is made possible due to funding from the Ile de France Region, which supports bioproduction efforts as part of its Ile-de-France Leader Bioproduction scheme, which was launched at the end of 2020.

About ART-TG
RT-TG is an Inserm innovation center located in Génopole d'Evry with the mission of promoting research excellence in gene and cell therapy by facilitating the transfer of therapeutic discoveries to clinical or industrial applications. ART-TG is a pre-industrial laboratory for testing technological innovation and pharmaceutical product and process development. ART-TG is now leading several innovative projects based on lentiviral vectors, or CRISPR genome editing tools for ex vivo uses, focusing on immunotherapy and hematology. ART-TG is a subsidiary of the industrial integrator MAGENTA (MAnufacturing Cell and GEN Therapy Advances) of the French Government Biomedicines Challenge.

About WhiteLab Genomics
WhiteLab Genomics, founded in 2019 by David Del Bourgo, Julien Cottineau, and Lucia Cinque, is a French start-up specialized in artificial intelligence solutions for biotherapies such as gene and cell therapies. Its proprietary technology enables multi-parametric analysis of complex biological data to optimize and reduce treatment development costs. WhiteLab Genomics makes this one-of-a-kind technology available to its clients through the Catalyst platform, which is available in SaaS mode. The start-up is presently based in Genopole - Evry, France's first biocluster, and Station F.